METHOCARBAMOL Drug Patent Profile
✉ Email this page to a colleague
When do Methocarbamol patents expire, and what generic alternatives are available?
Methocarbamol is a drug marketed by Dr Reddys, Marsam Pharms Llc, Am Regent, Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Monterey Pharms Llc, Mylan Institutional, Navinta Llc, Sagent Pharms Inc, Slate Run Pharma, Somerset Theraps Llc, Able, Am Therap, Ani Pharms, Ascot, Aurobindo Pharma Ltd, Austarpharma Llc, Beximco Pharms Usa, Chartwell Molecular, Clonmel Hlthcare, Dbl Pharms, Fosun Pharma, Granules, Heather, Hetero Labs Ltd Iii, Hikma Intl Pharms, Impax Labs, Inwood Labs, Ivax Sub Teva Pharms, Kv Pharm, Mikart, MLV, Mylan, Nylos, Oxford Pharms, Pioneer Pharms, Prinston Inc, Puracap Pharm, Purepac Pharm, Roxane, Sandoz, Solvay, Sun Pharm Industries, Superpharm, Tablicaps, Upsher Smith, Watson Labs, Mcneil, Par Pharm, and Stevens J. and is included in seventy-four NDAs.
The generic ingredient in METHOCARBAMOL is aspirin; methocarbamol. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; methocarbamol profile page.
Summary for METHOCARBAMOL
Recent Clinical Trials for METHOCARBAMOL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Allucent | Phase 3 |
Arthritis Innovation Corporation | Phase 3 |
Prisma Health-Upstate | Phase 4 |
Pharmacology for METHOCARBAMOL
Drug Class | Muscle Relaxant |
Physiological Effect | Centrally-mediated Muscle Relaxation |